ArticleBMJ (Clinical research ed.)2024
GLP-1 agonists: US sees 700% increase over four years in number of patients without diabetes starting treatment.
Article in BMJ (Clinical research ed.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07702461 (Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists), which is not on this map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists
Who cites it
37 citing papers in PubMed.
- Causes and consequences of discontinuation of GLP1RAs or tirzepatide.Nature reviews. Endocrinology · 2026Review
- Skin Impacts and Tradeoffs of GLP-1 Therapy: Improved Patient-Reported Outcomes of Inflammatory Skin Disease in the Era of "Ozempic Face".Dermatology and therapy · 2026Article
- New Obesity Definition and Clinical Obesity Prevalence for Global Metabolic Bariatric Surgery.JAMA network open · 2026Article
- How Negative Controls Are Used in Pharmacoepidemiology: A Methodological Scoping Review of Real-World Observational Studies of Glucagon-Like Peptide-1 Receptor Agonists.Pharmacoepidemiology and drug safety · 2026Article
- GLP-1 receptor agonist medications for weight loss: Sociodemographic patterns of awareness, use, and access in a U.S. national cohort.Annals of epidemiology · 2026Article
- Perceptions of Glucagon-like Peptide 1 Receptor Agonists Among Individuals With Knee Osteoarthritis and Excess Weight: A Qualitative Study.ACR open rheumatology · 2026Article
- Phenome-wide analysis of downstream health outcomes following second-line antidiabetic agent prescriptions in All of Us.Nature communications · 2026Article
- Glucagon-like peptide-1 receptor agonist, semaglutide, attenuates intravenous self-administration of fentanyl in female rats.bioRxiv : the preprint server for biology · 2026Article
- Review
- How does type 2 diabetes modify the risk of Alzheimer's disease?Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Review
- Joint Society Statement From the Society for Endocrinology (SfE), the British Thyroid Association (BTA) and the British Association of Endocrine and Thyroid Surgeons (BAETS) Regarding the Association of GLP-1 Agonists and Thyroid Cancer.Clinical endocrinology · 2026Article
- Depression and Anxiety Among Individuals Receiving Incretin Mimetic Medications: A Saudi Cross-Sectional Study.Healthcare (Basel, Switzerland) · 2026Article
- Effects of Glucagon-like Peptide-1 Receptor Agonists on Skin Homeostasis and Skin Aging Processes.Journal of clinical medicine · 2026Review
- Nutritional Vulnerability in RYGB Unmasked by GLP-1 Therapy.ACG case reports journal · 2026Article
- Cardiovascular-Kidney-Metabolic Medication Eligibility Across National Survey, Community-Based, and Ambulatory Healthcare Samples.JAMA cardiology · 2026Article
- Managing Aesthetic Needs in Prescription Medication-Driven Rapid Weight Loss Patients: Results of an International Consensus. The Clinician Perspective.Journal of cosmetic dermatology · 2026Article
- Association of GLP-1 receptor agonist use with psychiatric outcomes in adults with type 2 diabetes: a target trial emulation.Diabetes research and clinical practice · 2026Article
- Glucagon-like peptide-1 receptor agonists for obesity: Growing popularity met with growing questions over safety.PLoS medicine · 2026Article
- Review
- Too Big to Lose Weight: How Pharmaceuticalization Corrupts the Right to Health.Health and human rights · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
39043396What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.